Real-World Data Show Regorafenib on Par With TAS-102 in Meta

A real-world comparison finds similar overall survival in patients with refractory metastatic CRC treated with either regorafenib or trifluridine/tipiracil (TAS-102).

Related Keywords

Salt Lake City , Utah , United States , University Of Utah , Christopher Nevala Plagemann , Huntsman Cancer Institute , Drug Administration , Journal Of The National Comprehensive Cancer Network , National Comprehensive Cancer Network , Flatiron Health , Salt Lake , National Comprehensive Cancer , Colorectal Cancer , Biologic Therapy , Toxicology , Refractory , Cancer , Alignant Neoplasia , Arcinoma , Targeted Therapy , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medical Technology , Antiangiogenesis , Angiogenesis Inhibitor , Evacizumab , Nhibitor Angiogenesis , Clinical Research , Clinical Trials , Linical Studies , Humanized Monoclonal Antibody ,